This post was originally published on this site
The company, which has notified the U.S. Food and Drug Administration, said the incident will likely delay production and distribution of the infant formula for a few weeks.
“Abbott has ample existing supply of EleCare and most of its specialty and metabolic formulas to meet needs for these products until new product is available,” it said in a statement https://abbo.tt/3NYJb5c.
Abbott will resume production of EleCare once the plant is re-sanitized and added that it will work to restart production of another infant formula Similac “as soon as possible”.
